Skip to content

Biotech Startup Mirxes Weighs $300 Million Singapore IPO

  • Company is targeting a valuation of $1 billion in share sale
  • Cancer screening tech startup could list as soon as next year
Updated on

Mirxes Pte, a Singapore-based biotechnology startup, is weighing an initial public offering in the city-state next year that could raise about $300 million, according to people with knowledge of the matter.

The company is in discussions with bankers about a potential offering that could value it at over $1 billion, said the people, who asked not to be identified as the process is private.